crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.
- DOI
- 10.1016/j.brci.2025.100025
- Published
- 2025 Dec
- Container
- Blood red cells & iron
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.brci.2025.100025,
title = {crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.},
author = {Rubic-Schneider T and Kaminski TW and Ledieu D and Garcia D and Hehlen J and Burnet-Merlin C and de Billy BC and Greutmann B and DeLise AM and Brzoska T and Bergeron R and Dubey RK and Pradhan-Sundd T and Krӧner F and Verneret M and Bruederle A and Hines PC and Gao X and Dajee M and Sundd P},
year = {2025},
journal = {Blood red cells \& iron},
doi = {10.1016/j.brci.2025.100025},
url = {https://doi.org/10.1016/j.brci.2025.100025}
}RIS
TY - JOUR TI - crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease. AU - Rubic-Schneider T AU - Kaminski TW AU - Ledieu D AU - Garcia D AU - Hehlen J AU - Burnet-Merlin C AU - de Billy BC AU - Greutmann B AU - DeLise AM AU - Brzoska T AU - Bergeron R AU - Dubey RK AU - Pradhan-Sundd T AU - Krӧner F AU - Verneret M AU - Bruederle A AU - Hines PC AU - Gao X AU - Dajee M AU - Sundd P PY - 2025 JO - Blood red cells & iron DO - 10.1016/j.brci.2025.100025 UR - https://doi.org/10.1016/j.brci.2025.100025 ER -
APA
T, R., TW, K., D, L., D, G., J, H., C, B., BC, D. B., B, G., AM, D., T, B., R, B., RK, D., T, P., F, K., M, V., A, B., PC, H., X, G., M, D., & P, S. (2025). crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.. Blood red cells & iron. https://doi.org/10.1016/j.brci.2025.100025
Source records
- pubmed · retrieved 2026-09-25T16:29:32.352Z